BMY - Bristol-Myers Squibb Company - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BMY is currently covered by 18 analysts with an average price target of $59.75. This is a potential upside of $11.29 (23.3%) from yesterday's end of day stock price of $48.46.

Bristol-Myers Squibb Company's activity chart (see below) currently has 191 price targets and 200 ratings on display. The stock rating distribution of BMY is 61.29% HOLD, 24.19% BUY and 14.52% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 67.44% with an average time for these price targets to be met of 669.77 days.

Highest price target for BMY is $73, Lowest price target is $39, average price target is $59.2.

Most recent stock forecast was given by AKASH TEWARI from JEFFERIES on 23-Apr-2025. First documented stock forecast 22-May-2013.

Currently out of the existing stock ratings of BMY, 38 are a HOLD (61.29%), 15 are a BUY (24.19%), 9 are a SELL (14.52%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$68

$20.1 (41.96%)

5 days ago
(23-Apr-2025)

2/3 (66.67%)

$19.47 (40.12%)

18

Buy

6 days ago
(22-Apr-2025)

3/4 (75%)

$20.88 (37.88%)

652

Hold

$54

$6.1 (12.73%)

$43

17 days ago
(11-Apr-2025)

1/4 (25%)

$3.29 (6.49%)

12

Hold

$62

$14.1 (29.44%)

$52

2 months 21 days ago
(07-Feb-2025)

6/8 (75%)

$5.15 (9.06%)

48

Hold

$65

$17.1 (35.70%)

$60

3 months ago
(28-Jan-2025)

8/15 (53.33%)

$6.24 (10.62%)

1103

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BMY (Bristol-Myers Squibb Company) average time for price targets to be met?

On average it took 669.77 days on average for the stock forecasts to be realized with a an average price target met ratio 67.44

Which analyst has the current highest performing score on BMY (Bristol-Myers Squibb Company) with a proven track record?

CHRIS SCHOTT

Which analyst has the most public recommendations on BMY (Bristol-Myers Squibb Company)?

Chris Schott works at JPMORGAN and has 6 price targets and 6 ratings on BMY

Which analyst is the currently most bullish on BMY (Bristol-Myers Squibb Company)?

Chris Schott with highest potential upside - $32.1

Which analyst is the currently most reserved on BMY (Bristol-Myers Squibb Company)?

Terence Flynn with lowest potential downside - -$8.9

Bristol-Myers Squibb Company in the News

Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy

Bristol-Myers Squibb recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company’s share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&P 500, experienced a 12%...

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?